Edition:
United States

Japan

Alzheimer's drug from Biogen to get speedy U.S. review

The U.S. Food and Drug Administration will conduct an expedited review of an experimental Alzheimer's drug from Biogen Inc and Japan's Eisai Co Ltd, the companies said on Friday, the first application in 17 years to be reviewed by the agency for a treatment of the mind-robbing disease.

Japan News Video

World News